N/A N=323 Comparison of Treatment for Hoarding Disorder
Hoarding Disorder
Primary: Saving Inventory-Revised (SI-R) — 64.5; 66.4; 45.9; 47.8 units on a scale — p=0.04
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=38 A Study on the Use of CorMatrix® ECM® for Femoral Arterial Reconstruction
Peripheral Vascular Disease
Primary: Device-Related Adverse Events — 0 Proportion of Participants that Experien
N/A N=30 A Pilot Study Comparing the Use of Low-target Versus Conventional Target Advagraf
Acute Graft Rejection · Diabetes
Primary: Number of Participants With New Onset Diabetes After Transplant (NODAT) or Acute Rejection — 2; 2 Participants
Phase 4 N=5 Improving Sleep Quality in Heart Failure
Sleep Disturbance · Heart Failure
Primary: Sleep Latency — -73.3; 21.9 minutes
Phase 3 N=205 Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis
Diabetic Gastroparesis
Primary: Gastroparesis Symptom Assessment (GSA), a Patient Reported Outcome Measure — -0.925; -0.896 score on a scale — p=0.881
Phase 2 N=62 Does Dapagliflozin Provide Additional Health Benefits To Dietary Counseling For Weight Loss?
Weight Loss
Primary: Change From Baseline in Insulin Sensitivity at Week 12 Via Oral Glucose Tolerance Test — 6.9; 11.1; 5.5; 6.5 mU/L
Phase 4 N=103 Determine the Clinical Advantage of IV vs PO Acetaminophen
Inguinal Hernia
Primary: PACU Visual Analogue Pain Scores — 2.13; 1.52; 2.88; 2.41 score on a scale
Phase 2 N=41 NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders
Chronic Myeloproliferative Disorders · Leukemia · Lymphoma
Primary: Day 100 TRM — 4 Participants
N/A N=32 Leg Thermotherapy for Intermittent Claudication
Peripheral Artery Disease
Primary: Exercise Tolerance Assessed by Measuring Distance (m) Walked in 6-minutes — 388.75; 414.96; 404.29; 419.73 meters
Phase 1 N=33 A Phase 1 Study to Evaluate PK, Safety and Tolerability of AMG 416
Secondary Hyperparathyroidism
Primary: Pharmacokinetic (PK) Parameter: Time to Maximum Drug Concentration (Tmax) of Plasma Etelcalcetide on Days 1 and 27 — 0.22; 0.22 hour
Phase 1 N=11 To Evaluate the Pharmacokinetic of Diacerein and Rhein After Maximum Use in Patients With Epidermolysis Bullosa (EB)
Epidermolysis Bullosa (EB) · Epidermolysis Bullosa Simplex · Dystrophic Epidermolysis Bullosa
Primary: Detectable Plasma Concentrations of Diacerein and Rhein — 3; 2; 0; 0 Participants
Phase 2 N=33 Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease
Chronic Lymphocytic Leukemia
Primary: Improvement in Quality of Remission: Number of Participants With Response Versus No Response by NCI Working Group Criteria Disease Status Change at Start/End of…
N/A N=26 Beet the Cold: The Effect of Inorganic Nitrate Supplementation in Individuals With Raynaud's Phenomenon
Raynaud Phenomenon
Primary: Peripheral Blood Flow — 3.7; 3.7; 4.1; 3.7 flux.mmHg-1
Phase 2 N=58 Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ)
Stomach Cancer · Gastric Cancer
Primary: Complete Pathologic Response Rate — 14 percentage of participants
N/A N=105 Veterans Coping Long-term With Active Suicide
Suicide
Primary: Changes in Columbia Suicide Severity Rating Scale (C-SSRS) - Behavior — 0.13; 0.18; 0.14; 0.05 log(attempts) — p=.13